Dr. Munaza Kulsum’s 2023 publication, co-authored with Manjunath Hulmani, examined oral isotretinoin in moderate-to-severe acne. The study focused on clinical response, adverse effects and laboratory monitoring, including lipid profile and liver enzymes.
The question
The study set out to examine clinical efficacy and adverse effects, with particular attention to lipid profile and liver enzymes. It recruited 60 patients older than 16 years in an outpatient setting. The published protocol used 20 mg/day of oral isotretinoin for four months with follow-up at specified intervals.
What was monitored
The paper describes clinical examination and laboratory monitoring, including liver enzymes and lipid profile. It also reports a urine pregnancy test before treatment for women of child-bearing potential. Cheilitis and xerosis were among the clinical adverse effects described, while lipid changes were monitored.
How patients should read this
A research dose is not a personal prescription. The study tells us what happened in one defined cohort under a particular protocol. Isotretinoin prescribing still needs individual assessment, contraindication review, pregnancy precautions and follow-up. The useful clinical lesson is the importance of monitoring and counselling — not copying 20 mg/day from the paper.
Connection with her postgraduate work
SSIMS’s dissertation page lists Dr. Munaza Kulsum’s dissertation on clinical efficacy of oral isotretinoin in moderate-to-severe acne with effects on liver enzymes and lipid profile, guided by Dr. Manjunath Hulmani. The later publication closely reflects that research theme.
Related clinic page: General Dermatology